Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple blood test could spot 8 cancers early using AI

NCT ID NCT06717295

Diagnosis Sponsor: Javier Toledo Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new AI-powered blood test that looks at platelets and immune cells to find early signs of eight different cancers, including lung, breast, and pancreatic cancer. Researchers will collect blood samples from 6,000 adults aged 40 and older, both with and without cancer, to see if the test can accurately tell them apart. The goal is to create a non-invasive way to catch cancer early and track how well treatments are working.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
DiNanoQ blood test and DiNanoTrack blood test
What this could lead to
If successful, this could lead to a simple blood test that catches several cancers early and helps doctors see if treatment is working.
What could go wrong
This is an early observational study, not a treatment trial. The test may not be accurate enough for widespread use, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 6,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The CCANED-CIPHER study will enroll a diverse, geographically dispersed population to ensure the generalizability and robustness of its findings. The study is divided into two phases, utilizing up to 10 medical centers globally across the United Kingdom (UK), Europe, America, and Asia. Phase 1 (CCANED): Participants: 5,000 adults aged 40 years or older. * Cancer Patients: 3,500 individuals with confirmed diagnoses of common cancers. * Healthy Controls: 1,500 age-matched cancer-free individuals. Recruitment Strategy: Participants will be identified and enrolled through the participating medical centers, ensuring a representative sample across different geographical locations. Phase 2 (CIPHER): Participants: 1,000 adults aged 40 years or older diagnosed with HCC or NSCLC across stages I to IV. Recruitment Strategy: Cancer patients will be recruited from the participating cancer centers, ensuring a wide representation of disease stages and treatment backgrounds.

Ages

40 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Phase 1 (Common Cancer Early Detection - CCANED) Inclusion Criteria: * Age: Adults aged 40 years or older. * Confirmed diagnosis of one of the following common cancers: Non-Small Cell Lung Cancer (NSCLC), Glioblastoma Multiforme (GBM), Colorectal Cancer, Hepatocellular Carcinoma (HCC), Breast Cancer, Prostate Cancer, Ovarian Cancer, Pancreatic Cancer. Exclusion Criteria: * Currently pregnant. * Presence of any active infectious diseases. * Use of anticoagulant or antiplatelet drugs within the past 2 weeks. * Any medical or psychological conditions that may affect the participant's ability to comply with study procedures. Phase 2 ( Cancer Immuno-Profiling of Hematologic and Extracellular RNA - CIPHER) Inclusion Criteria: * Adults aged 40 years or older. * Confirmed diagnosis of: Hepatocellular Carcinoma (HCC), Non-Small Cell Lung Cancer (NSCLC) * Willingness to provide blood samples at the specified intervals (baseline, 6 weeks, and 6 months post-therapy initiation). Exclusion Criteria: * Presence of another malignancy unless it has been in remission for at least 5 years. * Significant uncontrolled co-morbid conditions that may interfere with study participation or outcomes.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brest cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer carcinoma of liver and intrahepatic biliary tract colorectal cancer colorectal neoplasm glioblastoma glioma susceptibility 1 hepatocellular carcinoma lung cancer lung neoplasm malignant pancreatic neoplasm neoplasm non-small cell lung carcinoma ovarian cancer Pancreatic cancer, adult prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brest cancer Colorectal cancer Glioblastoma (GBM) Liver carcinoma Lung cancer (NSCLC) Ovarian cancer Pancreatic cancer, adult Prostate cancers

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    3 sites in 2 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Babraham Research Institute

    ENROLLING_BY_INVITATION

    Cambridge, CB22 3AT, United Kingdom

  • Dysplasia Diagnostics Limited

    RECRUITING

    London, W1W 7LT, United Kingdom

    Contact Email: •••••@•••••

  • NSIA- Lagos University Teaching Hospital Cancer Centre

    RECRUITING

    Lagos, Nigeria

  • Various Cancer Centres

    ACTIVE_NOT_RECRUITING

    Rosario, Argentina

More trials for these conditions

Other studies related to the condition(s) this trial covers.